The Ebola Bundibugyo outbreak in the Democratic Republic of Congo has reached approximately 600 suspected cases and 139 deaths as of Wednesday, with two confirmed cases in Uganda and a new case in South Kivu — an area under the control of Rwanda-backed M23 rebels, which complicates humanitarian access. The World Health Organization declared a Public Health Emergency of International Concern last Sunday, unusually before convening the standard emergency committee. The Bundibugyo strain carries no licensed vaccine or approved treatment. The US announced a travel ban on non-citizens who have recently visited DRC, Uganda, or South Sudan within the previous 21 days; one flight bound for Detroit was diverted to Canada after a passenger from DRC was onboard. Meanwhile, The Guardian reported that the US CDC is sending one additional person to the region, that the NIH Ebola laboratory in Frederick, Maryland has been shuttered with staff laid off, and that USAID funding to DRC collapsed from $1.4 billion in 2024 to $21 million so far in 2026. Secretary of State Rubio this week criticised the WHO’s response while the US continues to withhold the $130 million in annual WHO funding it announced it was ending in early 2025.
The received wisdom
The liberal-internationalist case on this outbreak is essentially complete and does not need much embellishment: the US built, over decades, the most capable global disease surveillance and response infrastructure in the world. It embedded CDC teams in countries like DRC — which has deep experience managing Ebola outbreaks — provided the funding that kept frontline community health workers operating, and maintained laboratory capacity that could identify, sequence, and begin developing countermeasures against novel variants faster than any other institution on the planet. All of that is now gone or going. The travel ban the US has substituted is, as Africa CDC put it, liable to “create fear, damage economies, discourage transparency, complicate humanitarian and health operations, and divert movement toward informal and unmonitored routes — potentially increasing public health risks rather than reducing them.” The United States has not reduced its exposure to Ebola; it has simply made it more likely that the outbreak will be larger, longer, and more globally spread when it eventually becomes an American problem. On this reading, the administration has traded prevention — cheap, effective, and invisible to voters — for theater — visible, emotionally satisfying, and counterproductive.
A different read
The left-liberal analysis is largely correct on the public health mechanics, and it deserves to be said so plainly. The Guardian’s reporting on the collapse in US support for DRC — $1.4 billion in 2024 down to $21 million in 2026 — is not a rounding error. It is the elimination of an entire layer of the global health security architecture. Kristian Andersen of Scripps Research is quoted saying “this outbreak should have been detected weeks ago” and that the US “has stopped playing the role.” These are serious scientists making falsifiable empirical claims, not political advocacy.
Where the analysis is incomplete is in the political economy of why this happened and what, if anything, can be done about it within the current domestic political constraints. The bipartisan consensus that sustained American global health investment — which reached its peak during the Obama administration’s response to the 2014-2016 West African Ebola crisis, when the US deployed approximately 3,000 military personnel to Liberia — was always more fragile than its proponents acknowledged. It rested not on a genuine public understanding of why investment in DRC’s health infrastructure protected Americans at home, but on elite consensus and institutional momentum. When that elite consensus fractured — accelerated by distrust of public health institutions during COVID-19, the perceived failures of the WHO’s early pandemic response, and the politically successful narrative that global health funding represented misappropriation of American taxpayer money — the institutional momentum collapsed with remarkable speed.
The pattern here is not unique to public health. American commitments to institutions it helped build — from the WTO to NATO to the IAEA — have historically depended on elite advocacy rather than popular understanding. When elite advocacy fails or is actively undermined, the commitments dissolve. Rebuilding them requires not just making the argument again but rebuilding the domestic political foundation that made the argument credible.
The Rubio gambit — criticising the WHO for being slow while gutting the American capacity that would allow a faster response — is politically coherent, even if it is analytically dishonest. The Guardian noted that this pattern has a logic: by blaming an international institution for failures caused partly by the withdrawal of American support, the administration can simultaneously appear engaged on the issue and avoid accountability for the policy choices that produced the weakness. This is not a new trick — it is a version of the same pattern deployed against the UN, the WTO, and the World Bank — but it is particularly dangerous in a disease outbreak context, because the bureaucratic dynamics of international health response genuinely are slow and genuinely do need reform. The WHO has real accountability problems. Exploiting those problems as cover for dismantling the domestic infrastructure that makes any international response possible is a different thing entirely.
What the Bundibugyo outbreak may produce — and this is not certain — is a practical test of whether the current configuration of American global health capacity can manage a serious outbreak that begins outside its borders. The 2014 West African crisis eventually reached American soil: a Liberian man died in a Dallas hospital, two American nurses were infected, and the political temperature around the response rose sharply before the outbreak was contained. The CDC surge that followed — trained response teams, airport screening, coordinated international deployment — depended on exactly the institutional infrastructure that has now been dismantled. Whether history repeats, and at what cost, is the question the current policy framework poses.
What to watch
- Whether the Goma case — in North Kivu’s M23-controlled capital — can be contained given the restriction on humanitarian access. An outbreak spreading through a conflict zone with no functional medical infrastructure represents a scenario that travel bans cannot address.
- The vaccine timeline: experts estimate six to nine months before a Bundibugyo-specific vaccine could be available. The NIH laboratory that would normally be doing the fastest early-stage work on monoclonal antibodies has been shuttered. Whether alternative laboratory capacity — European, African, or private — can close that gap is an empirical question with large consequences.
- Congressional pressure for emergency CDC/USAID restoration: if cases reach Europe or North America in significant numbers, the domestic political calculation changes rapidly, and there may be appetite for emergency appropriations to restore at least some response capacity.
- Rubio’s WHO critique: whether it produces any concrete institutional reform demand — which would at least be actionable — or remains pure deflection. A serious critic of the WHO would propose specific governance changes; a purely political critic would not.
— J